Form 4: Quoin COO Denise Carter Receives Stock Option Grant

Quoin Pharmaceuticals' Chief Operating Officer, Denise Carter, was granted 318,750 stock options with an exercise price of $7.37 per American Depositary Share.

Summary

• Denise P. Carter, Chief Operating Officer and Director of Quoin Pharmaceuticals, Ltd. (QNRX), was granted 318,750 derivative securities in the form of Share Options (Right to Buy).
• The options have an exercise price of $7.37 per American Depositary Share (ADS).
• Each ADS represents thirty-five ordinary shares of Quoin Pharmaceuticals, Ltd.
• The options will vest in four annual installments: 20% on February 4, 2027, 20% on February 4, 2028, 20% on February 4, 2029, and 40% on February 4, 2030.
• The options have an expiration date of February 4, 2036.
• Following this transaction, Denise Carter beneficially owns 318,750 derivative securities.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as the option grant aligns the Chief Operating Officer's financial interests with the company's long-term performance, which is generally favorable for shareholder value.

Positives

• The grant of stock options to the Chief Operating Officer aligns management's long-term interests with those of shareholders, incentivizing performance.
• The multi-year vesting schedule encourages retention and sustained executive focus on company growth over several years.

Industry Context

StockSavvy.ai notes that executive stock option grants are a standard practice in the pharmaceutical and biotechnology sectors, serving as a key component of compensation packages designed to attract and retain top talent while aligning executive incentives with long-term shareholder value creation.

Comparison to Industry Standards

• StockSavvy.ai observes that the size of this option grant (318,750 ADSs) for a Chief Operating Officer is within the typical range for C-suite executives at small to mid-cap pharmaceutical companies, reflecting common industry practices for performance-based compensation.
• The ten-year term and multi-year vesting schedule are consistent with industry benchmarks for long-term incentive plans, aiming to foster sustained commitment and strategic execution.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive incentives with long-term company performance and shareholder value creation.
• Employees: May signal stability in executive leadership and a commitment to long-term growth, potentially boosting morale.

Next Steps

• Vesting of 20% of options on February 4, 2027.
• Vesting of 20% of options on February 4, 2028.
• Vesting of 20% of options on February 4, 2029.
• Vesting of 40% of options on February 4, 2030.

Key Dates

Keywords

Quoin Pharmaceuticals, QNRX, Denise Carter, Stock Options, Executive Compensation, Insider Transaction, Form 4, American Depositary Shares, Biotechnology, Pharmaceuticals